Human Microbiome - Major Revenue Growth is Predicted in Near Future

Overview of this Study:

This study involved four major activities in estimating the current size of the human microbiome market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Major Growth Driving Factors:

The major factors driving the growth of the market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the total size of the human microbiome market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and market have been identified through extensive secondary research
# The revenues generated from the human microbiome business of leading players have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Projected Surge in Global Revenue:

The global human microbiome market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029.

Data Triangulation:

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition:

The human microbiome refers to a collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that live within and on the human body. These microorganisms interact with each other and with the human host in a complex and dynamic manner, playing important roles in a range of physiological processes, including digestion, immune function, and metabolism. The human microbiome is highly diverse and varies between individuals and different regions of the body. The market encompasses various sectors, including research tools, diagnostics, therapeutics, and consumer products, aimed at leveraging the knowledge and potential of the microbiome to improve human health and well-being.

This includes the development and commercialization of microbiome-based therapies, such as live biotherapeutic products (LBPs), probiotics, prebiotics, and other microbial interventions, as well as the development of diagnostic tools for assessing and monitoring the microbiome.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Key Players:

The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Human Microbiome Market - Major Revenue Surge is Predicted by 2029

Report Objectives:

# To define, describe, and forecast the human microbiome market based on products, type, application, and disease.

# To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends).

# To strategically analyse micro markets with respect to individual growth trends, future prospects, and contributions to the overall human microbiome market.

# To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

# To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.

# To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the human microbiome market.

Download PDF Brochure for More Details@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the total size of the human microbiome market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and market have been identified through extensive secondary research
# The revenues generated from the human microbiome business of leading players have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Projected Revenue Growth During Forecast Period:

The global human microbiome market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029.

Major Growth Driving Factors:

The major factors driving the growth of the market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.

Data Triangulation:

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Global Geographical Segmentation:

Asia Pacific: The fastest-growing region in the human microbiome market.

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes.

Key Players:

The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Human Microbiome Market: Prominent Players, Globally..!

Overview of This Study:

In order to estimate the present size of the human microbiome market, this study includes four primary actions. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The following stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.

Global Growth Driving Factors:

The market is predicted to rise at a rapid pace due to the growing demand for natural and holistic treatments as well as the booming need for individualized medication. Nonetheless, market expansion is anticipated to be somewhat constrained by our incomplete knowledge of microbial interactions.

Projected Surge in Revenue Generation:

With a predicted revenue of $0.3 billion in 2023 and a projected compound annual growth rate (CAGR) of 36.1% from 2023 to 2029, the worldwide human microbiome market is expected to reach $1.7 billion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Leading Players:

The market for human microbiome is highly consolidated, with key players strategizing to capture majority of the market. Prominent players in the market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Different Growth Strategies Adopted by Them:

These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the human microbiome market.

Seres Therapeutics, Inc. (US)

The goal of Seres therapies is to create microbiome therapies to cure dysbiosis-related illnesses. The company has a robust pipeline of drugs in different stages of development, such as SER-287, which is being developed for the treatment of inflammatory bowel disease (IBD), and SER-109, which is intended to treat recurrent Clostridium difficile infection (CDI).

Seres Therapeutics' cutting-edge technological platform, which integrates bioinformatics, machine learning, and high-throughput DNA sequencing to find possible treatment candidates from the human microbiome, is another aspect that helps explain the company's dominance in the microbiome sector. With the help of this platform, the business may create tailored treatments meant to enhance patient outcomes and return the microbiome to its natural equilibrium.

Enterome (France)

Enterome's creative approach to creating microbiome-based medicines and diagnostics has made it a major participant in the human microbiome market. It is creating a series of diagnostic tests based on the microbiota. Microbial biomarkers are used in these tests to help diagnose and track a number of conditions, such as liver disorders, colon cancer, and inflammatory bowel disease.

To further enhance its R&D endeavors, Enterome has also formed a number of strategic alliances. For instance, the business and Takeda Pharmaceuticals have been working together since 2016 to develop microbiome-based medicines for the management of inflammatory bowel disease. The business and Nestlé Health Science collaborated in 2022 to create treatments and diagnostics based on the microbiome.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

4D pharma plc (UK)

Because of its creative approach to the development of microbiome-based treatments, 4D Pharma Plc is one of the major participants in the human microbiome market. Utilizing a proprietary platform technology known as MicroRx, the business is able to recognize, separate, and cultivate live bacteria from the gut microbiome. Through the process of identifying and isolating helpful bacteria with therapeutic properties, this approach allows the company to create accurate and focused medicines for particular ailments.

Furthermore, 4D Pharma is developing a robust portfolio of microbiome-based treatments at different phases of development, including Phase II and Phase III clinical trials to treat diseases like asthma, cancer, and irritable bowel syndrome. In addition, the company collaborates with major pharmaceutical companies such as MSD and AstraZeneca, which provides it with access to their expertise and resources.

Geographical Growth Dynamics:

Asia Pacific: The fastest-growing region in the human microbiome market.

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes.

Human Microbiome: Global Market Growth Dynamics & Future Trends

 Overview:

In order to estimate the current size of the human microbiome market, this study involved four major activities. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to estimate the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.

DRIVER: Collaborative efforts between microbiome industry and academia for microbiome research

To progress microbiome research, the academic community and the microbiome industry have formed cooperative efforts. In order to understand the intricate relationships between microbes and their hosts, this collaboration makes use of the knowledge and resources of both industries. While academia offers cutting-edge research, scientific rigor, and a diversity of academic perspectives, industry contributes significant funding, technological advancements, and access to large-scale datasets. Together, they quicken the process of gaining new understanding of the function of the microbiome in health and illness, opening the door to creative treatments, diagnostics, and personalized medicine strategies. This cooperative strategy creates a mutually beneficial relationship that advances science and facilitates the practical application of microbiome research.

RESTRAINT: Adverse impact of complex regulatory policies on commercialization of microbiomes

The commercialization of microbiomes may be negatively impacted by intricate regulatory policies. Navigating regulatory frameworks presents special challenges for microbiome research due to its dynamic and rapidly evolving nature. Protracted approval procedures, exorbitant expenses, and exacting specifications may impede the prompt creation and introduction of microbiome-driven products and treatments.

Small and medium-sized businesses (SMEs) and startups are disproportionately affected by these barriers, which make it harder for them to compete with more established, larger businesses. Additionally, inconsistent laws in various nations or regions can obstruct access to international markets and hinder commercialization efforts even more. To encourage innovation and guarantee the responsible and effective commercialization of microbiome-based technologies, regulatory bodies and industry stakeholders must work together to streamline and harmonize regulatory policies, promote clear guidelines, and foster collaboration.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Revenue Growth Dynamics:

The global human microbiome market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029.

Data Triangulation:

Following the completion of the market size estimation process, the entire market was divided into multiple segments. Data triangulation and market breakdown procedures were used when appropriate to finish the entire market engineering process and obtain precise statistics for every segment. Through an analysis of numerous variables and patterns from the supply and demand sides, the data was triangulated.

Market Definition:

The term "human microbiome" describes a group of microorganisms that reside on and within the human body, such as bacteria, viruses, fungi, and other microbes. These microbes have intricate and dynamic interactions with both the human host and one another. They are crucial to many physiological processes, such as metabolism, immunological response, and digestion. The microbiome of humans is extremely varied and differs amongst people and bodily parts. The market consists of a number of industries, such as consumer goods, diagnostics, treatments, and research tools, all of which are focused on using the microbiome's potential and knowledge to enhance human health and wellbeing. This covers the creation of diagnostic tools for evaluating and tracking the microbiome as well as the development and marketing of microbiome-based treatments, such as live biotherapeutic products (LBPs), probiotics, prebiotics, and other microbial interventions.

Geographical Growth Scenario:

Asia Pacific is the human microbiome market's fastest-growing region.

Due in large part to growing demand for personalized medicine, advances in sequencing technologies, and growing recognition of the role of the microbiome in health and disease, the Asia Pacific human microbiome market is anticipated to grow at the highest CAGR during the forecast period. Due to the growing emphasis on personalized medicine and preventative healthcare, which is fueling the demand for human microbiomes, the Asian market has also attracted a lot of attention from international players.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Global Key Players:

The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Recent Developments:

# In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza’s Ibex campus in Visp, Switzerland.

# In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

# In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health.

Advancements in Human Microbiome Research - & It's Impact on Global Industry Revenue

Overview of This Study:

In order to estimate the current size of the human microbiome market, this study involved four major activities. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to estimate the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.

Market Size Estimation:

The entire market size for human microbiomes was estimated and validated using both top-down and bottom-up methods. The size of different market subsegments was also extensively estimated using these techniques. The research methodology used to estimate the market size includes the following:

# A great deal of secondary research has been done to identify the major players in the market and industry.
# Primary and secondary research has been used to determine the revenues that leading players in the human microbiome market generate.
# Primary sources have been used to verify all percentage shares, splits, and breakdowns that have been calculated using secondary sources.

Projected Surge in Revenue Generation:

With a predicted revenue of $0.3 billion in 2023 and a projected compound annual growth rate (CAGR) of 36.1% from 2023 to 2029, the global human microbiome market is expected to reach $1.7 billion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Major Growth Influencing Factors:

Technological developments and the growing acceptance of personalized medicine are two major factors propelling the market's expansion. But the lack of knowledge about microbial interactions and regulatory obstacles may prevent the market from expanding.

Geographical Growth Dynamics:

The market for human microbiomes in 2023 was dominated by North America.

The market is divided into four geographic segments: North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to maintain its dominance of the market well into the forecast period, having done so in 2023. The North American market is expanding due to factors such as a well-established research infrastructure, technological advancements, the growing demand for precision medicine, a supportive regulatory environment, a robust biotechnology and healthcare industry, and easy access to funding and investment. The high cost of some human microbiomes, however, is impeding the market's growth and may prevent some customers—particularly smaller research institutions or clinics with tighter budgets—from adopting these products.

Global Leading Companies Operating in This Industry:

The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Recent Developments:

# In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza’s Ibex campus in Visp, Switzerland.

# In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

# In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Key Stakeholders:

# Manufacturers and distributors of human microbiome products
# Pharmaceutical and biotechnology companies
# Market research and consulting firms
# R&D centers
# Researchers and scientists
# Academic & research institutes

Human Microbiome Research – Current & Emerging Trends

 Introduction

 

The human microbiome is a complex ecosystem of microorganisms, including bacteria, viruses, fungi, and protozoa, that inhabit various parts of the human body, such as the gut, skin, oral cavity, and reproductive tract. Recent advances in technology have enabled the study of the human microbiome in unprecedented detail, leading to a surge in research activity in this field. In this blog post, we will discuss current and emerging trends in human microbiome research.

 

Current Trends in Human Microbiome Research

 

1.      Gut Microbiome and Disease

 

The gut microbiome has been the focus of much research in recent years due to its role in regulating human health. Several studies have linked gut microbiome dysbiosis (an imbalance of bacterial populations) to a range of diseases, including obesity, type 2 diabetes, inflammatory bowel disease, and even cancer. Researchers are now investigating how modulating the gut microbiome can be used to prevent and treat these diseases.

 

2.      Metagenomics and Bioinformatics

 

The study of the human microbiome requires advanced techniques in metagenomics and bioinformatics. Metagenomics involves sequencing the DNA of all microorganisms present in a sample, while bioinformatics involves analyzing and interpreting the resulting data. The development of these techniques has enabled researchers to identify previously unknown microorganisms and their roles in the human microbiome.

 

3.      Microbiome and the Brain

 

Research has shown that the gut microbiome can influence brain function and behavior, a concept known as the gut-brain axis. Studies in animals have demonstrated that manipulating the gut microbiome can affect anxiety, depression, and cognition. Researchers are now investigating the potential of microbiome-based therapies for mental health disorders.

 

Find Out More Details | Download PDF Brochure, Here..!

 

4.      Microbiome and Immune System

 

The human immune system and microbiome are closely interconnected. The microbiome can modulate immune function, and in turn, the immune system can shape the composition of the microbiome. Research in this area is focusing on how the microbiome and immune system interact and how these interactions can be harnessed to prevent and treat diseases.

 

5.      Microbiome and Personalized Medicine

 

Advances in microbiome research are paving the way for personalized medicine. The human microbiome is unique to each individual, and by understanding an individual's microbiome composition, doctors can tailor treatments to optimize efficacy and minimize side effects. Microbiome-based therapies are already being developed for diseases such as Clostridioides difficile infection and inflammatory bowel disease.

 

Emerging Trends in Human Microbiome Research

 

1.      Skin Microbiome

 

The skin is the largest organ in the human body and is home to a diverse community of microorganisms. Recent studies have shown that the skin microbiome plays a critical role in skin health and disease. Research in this area is still in its early stages, but it is believed that the skin microbiome may hold the key to developing new treatments for conditions such as eczema, acne, and psoriasis.

 

2.      Respiratory Microbiome

 

The respiratory tract is another area of the human body that is home to a diverse microbiome. Research in this area is still in its infancy, but recent studies have suggested that the respiratory microbiome may play a role in lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). By understanding the respiratory microbiome, researchers hope to develop new treatments for these diseases.

 

3.      Microbiome Engineering

 

Microbiome engineering involves intentionally altering the composition of the microbiome to achieve a desired outcome. This approach has the potential to transform the treatment of many diseases by modulating the microbiome to promote health. For example, microbiome engineering could be used to enhance the efficacy of cancer treatments or to prevent infections in hospitalized patients.

 

You Can Also Connect With Our Research Experts to Solve Your Queries

 

Conclusion:

 

Overall, research in the field of human microbiome holds immense promise for improving human health and treating a range of diseases. As technology continues to advance, we can expect to see further progress in this field, leading to improved understanding and new therapeutic approaches.

Human Microbiome Market worth $1,370 million by 2029 - Exclusive Report by MarketsandMarkets™

 The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. according to a new report by MarketsandMarkets™. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Browse in-depth TOC on "Human Microbiome Market”
183 – Tables
27 – Figures
188 – Pages

The drugs segment to account for the largest share of the product segment in the global human microbiome market in 2023.

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. The drugs segment is expected to account for the largest share of the human microbiome market in 2023. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs.

The therapeutics segment to account for the largest share of the market in 2023.

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2024. The increase in funding for R&D in microbiome-based therapies worldwide is the major factor driving the growth of this application segment. Technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes also support market growth

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

The infectious diseases segment to account for the largest share of the market in 2024.

Based on disease, the human microbiome market is segmented into five categories-infectious diseases, metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global human microbiome market in 2024. The large share of this segment can be attributed to the increasing research in microbiome-based products and their use in treating infectious diseases. The major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products currently in the pipeline.

The Asia Pacific region is the fastest-growing region of human microbiome research spending market from 2023 to 2029.

Based on region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2021. In 2021, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2023-2029.  Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=37621904

Browse Adjacent Market: Biotechnology Market Research Reports & Consulting

Related Reports:

Clinical Microbiology Market by Application (Food, Pharma, Manufacturing, Chemical, Environment), Disease (Respiratory, Std, Uti), Product (Instrument, Analyzer, Reagent), End User (Hospital, Diagnostic Lab, Academia) - Global Forecast to 2025

Human Microbiome Market worth $1,370 million by 2029

 Projected Revenue Surge:

The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029.

Major Growth Influencing Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

The drugs segment to account for the largest share of the product segment in the global human microbiome market in 2023.

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. The drugs segment is expected to account for the largest share of the human microbiome market in 2023. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs.

The therapeutics segment to account for the largest share of the market in 2023.

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2024. The increase in funding for R&D in microbiome-based therapies worldwide is the major factor driving the growth of this application segment. Technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes also support market growth

The infectious diseases segment to account for the largest share of the market in 2024.

Based on disease, the human microbiome market is segmented into five categories-infectious diseases, metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global human microbiome market in 2024. The large share of this segment can be attributed to the increasing research in microbiome-based products and their use in treating infectious diseases. The major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products currently in the pipeline.

The Asia Pacific region is the fastest-growing region of human microbiome research spending market from 2023 to 2029.

Based on region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2021. In 2021, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2023-2029.  Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Global Key Players:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).